Renee Tourdot, DVM
ASPCA Animal Poison Control Center
Welcome to Practical Toxicology, brought to you in partnership between Today’s Veterinary Practice and the ASPCA Animal Poison Control Center (APCC) (www.aspcapro.org/poison). This column provides practical clinical information about diagnosing and treating pets that have been exposed to potentially harmful substances.
- Provides 24-hour diagnostic and treatment recommendations by specially trained veterinary toxicologists
- Protects and improves animal lives through toxicology education, consulting services, and case data review
- Developed and maintains AnTox, an animal toxicology database system that identifies and characterizes toxic effects of substances in animals
- Works closely with human poison control centers to provide animal poisoning information
- Offers extensive veterinary toxicology consulting to organizations in industry, government, and agriculture.
If treating a patient that requires emergency care for poisoning, call the APCC at 888-426-4435.
Bromethalin-based rodenticide bait exposures have become increasingly common since the product became available in 1985.1 In 2015, the American Society for the Prevention of Cruelty to Animals Animal Poison Control Center received 2791 calls regarding exposures to bromethalin-based rodenticides.2
Exposures to this toxin present a unique challenge to clinicians. Once signs of convulsant syndrome—a neurologic syndrome caused by bromethalin toxicosis—have developed, prognosis for recovery is poor.3,4 Therefore, most clinicians seem aware that prompt and aggressive decontamination measures must be taken. However, if decontamination is too aggressive, iatrogenic hypernatremia can develop, and clinical hypernatremia can be just as life-threatening as a large bromethalin exposure.
To further complicate matters, clinical signs of hypernatremia can appear similar to the neurologic signs caused by bromethalin.5 If clinicians are not aware of, or monitoring for, a significant rise in the patient’s serum sodium level, hypernatremia may be mistaken for bromethalin toxicosis, resulting in incorrect treatment being instituted, which can worsen the patient’s prognosis.
This article provides guidance on how to treat patients with bromethalin exposure, while taking these challenges into consideration.
CONSIDER THIS CASE: EVALUATION
Dusty, a 6-year-old, 21-kg male castrated hound mix, is presented to an emergency hospital.
Shortly before presentation, Dusty’s owner found him carrying part of a rodenticide bait block and subsequently discovered a box of bait blocks on the basement floor. The owner believes the box of bait blocks was stored in the basement when she purchased the home 5 years ago, and she knows the box was not on the floor yesterday evening—the last time the owner was in the basement. There are no other pets in the home.
The Animal Poison Control Center (APCC) provides 24-hour diagnostic and treatment recommendations by specially trained veterinary toxicologists. If treating a patient that requires emergency care for poisoning, call the APCC at 888-426-4435.
Evaluation of the box label suggests that it once held 12 rodenticide bait blocks, each weighing 1 ounce. The box now contains 5 blocks plus the portion of the block the owner recovered from the dog’s mouth, which appears to be no larger than one quarter of a block. The label on the box says the active ingredient is 0.01% bromethalin.
Calculating Rodenticide Dosage
After evaluating patient history and the rodenticide itself, the dosage of bromethalin ingested needs to be calculated.
Based on patient history, it can be determined that Dusty was exposed to up to 6.75 ounces of the rodenticide (12−5.25 = 6.75 blocks). This is the worst-case scenario: the largest amount of bait that Dusty may have ingested is the missing portion of the block he was discovered carrying plus the missing blocks from the box.
To calculate the dosage ingested, the concentration of bromethalin in the bait needs to be determined.
- It is important to verify the rodenticide product, active ingredient, and concentration. This information should be taken directly from the packaging whenever possible.
- While most bromethalin-based rodenticides have a concentration of 0.01%, some commercial products have higher concentrations.
- A bromethalin concentration of 0.01% equals 0.1 mg of bromethalin in each gram of bait.
Using a concentration of 0.01%, the potential dosage ingested by Dusty can then be calculated:
- There are 28.4 grams in 1 ounce; therefore, Dusty may have ingested up to 192 grams of bait.
6.75 oz × 28.4 g/oz = 192 g
- If each gram of bait has 0.1 mg of bromethalin, Dusty may have ingested up to 19 mg of bromethalin.
0.1 mg/g × 192 g = 19.2 mg
- Finally, when 19 mg bromethalin is converted to mg/kg, Dusty may have ingested up to 9 mg/kg of bromethalin.
19 mg / 21 kg = 0.9 mg/kg
What does this mean? Is this a concerning exposure and, if so, how concerning? How aggressive does decontamination need to be? To answer these questions, the kinetics and toxicity of bromethalin need to be discussed.
Mechanism of Action & Kinetics
Bromethalin’s metabolite, desmethyl bromethalin, is primarily responsible for the uncoupling of oxidative phosphorylation in neuronal mitochondria.4 This results in a depletion of adenosine triphosphate from the cell, causing impairment of the sodium potassium pump.
When pump function is poor, sodium and fluid accumulate within the myelin sheaths. This edema accounts for the neurologic signs seen with bromethalin ingestion. Because the edema is within the myelin, this may also explain why traditional medical management of central nervous system edema, such as administration of diuretics and mannitol, has limited success.3
Bromethalin is excreted primarily through the bile, and it is suspected to undergo enterohepatic recycling because experimental studies have shown that multiple doses of activated charcoal are more effective at preventing the neurologic syndrome rather than a single dose.4
The clinical presentation of bromethalin toxicosis is dose dependent.
At lower exposure dosages (below the 50% lethal dose [LD50] of 3.65 mg/kg for dogs), a paralytic syndrome can develop, typically within 24 to 86 hours after exposure. This syndrome can cause hindlimb paresis and ataxia, and patients may recover from these signs over a period of weeks to months.
The signs of paralytic syndrome may progress, with development of absent deep pain sensation, upper motor neuron bladder paralysis, central nervous system depression, tremors, hyperesthesia, seizures, and death.1,4 This convulsant syndrome is usually, but not always, associated with larger exposures to bromethalin (above the LD50), and signs typically develop within 4 to 36 hours after ingestion.1,6,7
Cats demonstrate a similar clinical course to dogs, but are much more sensitive to bromethalin. The LD50 in cats is 0.54 mg/kg.4 Cats may also demonstrate ileus and resultant abdominal distention.1,5
Range of Dosages
The dosages cited for dogs and cats are medians, and any individual patient may be more sensitive to the effects of bromethalin.
The APCC has recorded hindlimb weakness occurring, although rarely, at dosages as low as
0.15 mg/kg in dogs, and tremors, depression, anorexia, and death occurring at dosages as low as 0.95 mg/kg, even though the experimental minimum lethal dose is reported to be 2.5 mg/kg.1,2
In cats, signs have occurred at dosages less than 0.24 mg/kg,2 and depression, ataxia, paresis, and death have occurred at dosages as low as 0.45 mg/kg.3
It also appears that dogs younger than 1 year of age may be more susceptible to the effects of bromethalin, which may be due to the immature blood–brain barrier in juveniles.
MANAGEMENT OF BROMETHALIN EXPOSURES
Based on the kinetics and toxicity of bromethalin, clinicians must take a conservative approach when deciding at what dosage to begin decontamination efforts and how aggressively to decontaminate. In addition, the time that has elapsed between exposure and decontamination must be taken into account (Table).
Decontamination Measures: Not Recommended
Alternative decontamination measures have been proposed and tried, yet no published evidence supports a recommendation for their clinical use at this time. The following measures are not recommended as the standard of care for bromethalin exposures.
Bromethalin is very lipophilic; therefore, in theory, intralipid emulsion therapy has the potential to reduce bromethalin concentrations in the body.9 If this therapy is to benefit the patient at all, it would likely be within the first several hours after an exposure because bromethalin is rapidly absorbed (peak plasma concentrations occur in 4 hours in rats).1,4 Reversal of the neurologic syndrome by intralipid emulsion is unlikely once the neurons are damaged. There is no solid evidence to support the routine use of intralipid therapy for bromethalin exposures at this time.
Cholestyramine is an indigestible ion exchange resin that has been successfully used for decontamination with other agents that undergo extensive enterohepatic recirculation, such as cholecalciferol and certain nonsteroidal anti-inflammatory drugs.10-13 Cholestyramine binds with bile acids in the intestine, preventing their reabsorption and producing an insoluble complex that is excreted in the feces.14 It is unknown at this time whether cholestyramine can be used successfully for bromethalin decontamination.
ADMINISTRATION of ACTIVATED CHARCOAL
Prior to decontamination with activated charcoal, consider administering an antiemetic. This may help reduce the risk for aspiration secondary to vomiting, as well as treat any nausea, which may encourage the patient to drink water.
The first dose of activated charcoal should be the largest dose (1 to 2 g/kg)2 and, ideally, contain a cathartic agent, such as sorbitol, unless the patient already has diarrhea. Subsequent doses should be half the original dose, with no cathartic included. If there is no evidence of charcoal in the rectum within 8 hours after the first dose, consider administering a warm water enema.6
The potential for activated charcoal to cause potentially lethal hypernatremia should not be underestimated. The mechanism for this effect is not definitively understood but is thought to result from the osmotic effect of the activated charcoal pulling water into the gastrointestinal tract.8 When administering activated charcoal (especially in repeated doses):
- It is vital to closely monitor the patient for hypernatremia: obtain a baseline serum sodium level prior to administering activated charcoal and recheck it before administering the next dose.
- Maintain the patient on intravenous balanced crystalloid fluids—such as lactated Ringer’s solution, Normosol R (hospira.com), or Plasma-Lyte (baxterhealthcare.com)—and provide unlimited access to oral water to help prevent hypernatremia.
- If a patient’s sodium level increases 5 mmol/L or more from baseline, provide free water (oral, enema, or 5% dextrose solution in water) and postpone the following dose until the sodium level has decreased.
CONSIDER THIS CASE: THERAPY
To summarize the information known about Dusty’s exposure, he was exposed to bromethalin while carrying the rodenticide block (< 4 H) and his worst-case-scenario exposure dosage is 0.9 mg/kg bromethalin. The Table recommends:
- Induction of emesis and
- Administration of activated charcoal Q 8 H for 48 H (6 doses total).
Because exposure may have taken place as early as the previous evening, it is important to perform a rectal examination and/or to evaluate the feces. If the feces are the color of the bait, a gentle warm water enema (5–10 mL/kg) to help decontaminate the colon is recommended.
Dusty is admitted to the hospital, and emesis is induced with apomorphine (0.04 mg/kg IV). A few small pieces of green material, suspected to be the bait, are seen in the vomitus. He is administered maropitant (1 mg/kg SC) as well as lactated Ringer’s solution IV at 1.5 times the maintenance rate of 60 mL/kg/day.
Dusty then receives 230 mL of 10% activated charcoal with sorbitol. His baseline sodium is 146 mmol/L. Seven hours after this treatment, Dusty’s sodium level is 151 mmol/L (mEq/L); his fluid rate is increased to 2 times the maintenance rate and he is given an enema.
One hour later, his serum sodium decreases to 148 mmol/L. Dusty is administered 115 mL of 10% activated charcoal without sorbitol. The remaining doses of charcoal are administered without complication.
Dusty is discharged from the hospital 54 hours after admission without developing signs of bromethalin toxicosis.
LD50 = 50% lethal dose.
- Dorman DC, Parker AJ, Buck WB. Bromethalin toxicosis in the dog. Part I: Clinical effects. JAAHA 1990; 26:589-594.
- ASPCA Animal Poison Control Center database, unpublished data, 2015.
- Dorman DC, Parker AJ, Buck WB. Bromethalin toxicosis in the dog. Part II: Selected treatments for the toxic syndrome. JAAHA 1990; 26:595-598.
- Dorman DC. Bromethalin. In Peterson ME, Talcott PA (eds): Small Animal Toxicology, 3rd ed. St. Louis: Elsevier Saunders, 2013, pp 471-478.
- Bates MC, Roady P, Lehner AF, et al. Atypical bromethalin intoxication in a dog: Pathologic features and identification of an isomeric breakdown product. BMC Vet Res 2015; 11:244.
- DeClementi C, Sobczak BR. Common rodenticide toxicoses in small animals. Vet Clin North Am Small Anim Pract 2012; 42:349-360.
- Dunayer E. Bromethalin: The other rodenticide. Vet Med 2003; 98:732-736.
- Plumb DC. Plumb’s Veterinary Drug Handbook, 7th ed. Stockholm, WI: PharmaVet Inc, 2011, pp 193-195.
- Dorman DC, Simon J, Harlin KA, Buck WB. Diagnosis of bromethalin toxicosis in the dog. J Vet Diagn Invest 1990; 2:123-128.
- Ferry DG, Grazeley LR, Busby WJ. Enhanced elimination of piroxicam by administration of activated charcoal or cholestyramine. Eur J Clin Pharmacol 1990; 39:599-601.
- Calvo M, Dominguez-Gil A. Interaction of naproxen with cholestyramine. Biopharmaceut Drug Dispos 1984; 5:33-42.
- Busch U, Heinzel G, Narjes H. The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. Eur J Clin Pharmacol 1995; 48:269-272.
- Thompson WG, Thompson GR. Effect of cholestyramine on the absorption of vitamin D3 and calcium. Gut 1969; 10:717-722.
- Questran oral suspension, cholestyramine oral suspension. Spring Valley, NY: Par Pharmaceutical Co, Inc, 2006.